Trial · NCT00965757
Adverse events63
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 63
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | 52 | 164 | 71 |
| other | Nasopharyngitis | Infections and infestations | Placebo (Double-blind, 1-28 Weeks) | 14 | 88 | 18 |
| other | Nasopharyngitis | Infections and infestations | Placebo/T-614 (Extension, 29-52 Weeks) | 15 | 68 | 17 |
| other | Pharyngitis | Infections and infestations | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | 10 | 164 | 14 |
| other | Pharyngitis | Infections and infestations | Placebo (Double-blind, 1-28 Weeks) | 6 | 88 | 6 |
| other | Pharyngitis | Infections and infestations | Placebo/T-614 (Extension, 29-52 Weeks) | 0 | 68 | 0 |
| other | Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | 20 | 164 | 25 |
| other | Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | Placebo (Double-blind, 1-28 Weeks) | 2 | 88 | 3 |
| other | Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | Placebo/T-614 (Extension, 29-52 Weeks) | 4 | 68 | 4 |
| other | Stomatitis | Gastrointestinal disorders | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | 18 | 164 | 26 |
| other | Stomatitis | Gastrointestinal disorders | Placebo (Double-blind, 1-28 Weeks) | 2 | 88 | 2 |
| other | Stomatitis | Gastrointestinal disorders | Placebo/T-614 (Extension, 29-52 Weeks) | 4 | 68 | 4 |
| other | Lymphocyte count decreased | Investigations | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | 29 | 164 | 48 |
| other | Lymphocyte count decreased | Investigations | Placebo (Double-blind, 1-28 Weeks) | 8 | 88 | 13 |
| other | Lymphocyte count decreased | Investigations | Placebo/T-614 (Extension, 29-52 Weeks) | 7 | 68 | 12 |
| other | Aspartate aminotransferase increased | Investigations | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | 27 | 164 | 44 |
| other | Aspartate aminotransferase increased | Investigations | Placebo (Double-blind, 1-28 Weeks) | 5 | 88 | 5 |
| other | Aspartate aminotransferase increased | Investigations | Placebo/T-614 (Extension, 29-52 Weeks) | 3 | 68 | 4 |
| other | Alanine aminotransferase increased | Investigations | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | 24 | 164 | 31 |
| other | Alanine aminotransferase increased | Investigations | Placebo (Double-blind, 1-28 Weeks) | 7 | 88 | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00965757/events